isf35
Biologicalexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2006 (NCT00779883)
Timeline
Indications
Mechanism of action
- CD40 ligandImmunity, active
CD40LG immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- isf35
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00942409 | Phase 2 | Jun 1, 2009 | Memgen, LLC, University of California, San Diego |
| NCT00849524 | Phase 2 | Jan 1, 2009 | Food and Drug Administration, Memgen, LLC, University of California, San Diego |
| NCT00772486 | Phase 1 | Sep 1, 2008 | Memgen, LLC, The Leukemia and Lymphoma Society |
| NCT00783588 | Phase 1 | May 1, 2007 | Memgen, LLC, University of Texas at Houston |
| NCT00779883 | Phase 1 | Jun 1, 2006 | Memgen, LLC, University of Texas at Houston |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Memgen, LLC | For profit | 5 | 3 | 2 | 2006 |
| University of California, San Diego | Academic/Hospital | 2 | 2 | 1 | 2009 |
| University of Texas at Houston | Academic/Hospital | 2 | 0 | 1 | 2006 |
| Food and Drug Administration | Government | 1 | 0 | 1 | 2009 |
| The Leukemia and Lymphoma Society | Academic/Hospital | 1 | 0 | 1 | 2008 |
5 organizations
Page 1 / 1